Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Centessa Pharmaceuticals plc (CNTA)

$40.50 +0.80% NASDAQ: CNTA · 15-min delayed
  • ALTRINCHAM, CHESHIRE,
  • Public · NASDAQ: CNTA
  • 129 employees
$6.1BMarket cap
$15.0MRevenue · FY2025
-$197.5MNet income
129Employees
CNTANASDAQ
2021IPO

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$15.0M
Net income
-$197.5M
Total assets
$687.5M
Market cap
$6.1B
Operating margin
-1384.6%
Net margin
-1316.9%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$15.0M
Operating expenses
$222.7M
Operating income
-$207.7M
Income tax
$1.8M
Net income
-$197.5M
EPS (basic)
$-1.46
EPS (diluted)
$-1.46

Balance sheet

Total assets
$687.5M
Current assets
$367.9M
Total liabilities
$160.6M
Current liabilities
$42.9M
Shareholders’ equity
$526.9M

Cash flow

Operating cash flow
-$193.8M
Investing cash flow
-$418.5M
Financing cash flow
$291.5M
Net cash flow
-$321.3M

Statements via Polygon.io (SEC filings)

NASDAQ: CNTA
$40.50 +0.80%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$12.43 $40.50

52-week range

Market cap
$6.1B
EPS (diluted)
$-1.46
Shares outstanding
151.4M
Open
Day range
Prev close
Volume
IPO date
May 28, 2021

Centessa Pharmaceuticals plc (CNTA) Stock Price

  • Reported a net loss of $197.5M in FY2025.
  • Trading near its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Centessa Pharmaceuticals plc.

Write a review
Newsroom

News about Centessa Pharmaceuticals plc

News & sentiment via Polygon.io

FAQ

Centessa Pharmaceuticals plc: frequently asked questions

Is Centessa Pharmaceuticals plc an American company?

Centessa Pharmaceuticals plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Centessa Pharmaceuticals plc publicly traded?

Yes — Centessa Pharmaceuticals plc is a publicly traded company. Its stock trades under the ticker symbol CNTA on the NASDAQ.

What does Centessa Pharmaceuticals plc do?

Centessa Pharmaceuticals plc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →